HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer

,

Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.

“The emphasis I will place is, first, we have 8 patients now, 4 with gastric cancer and 4 with colorectal cancer. The second point is that we have no dose limiting toxicities observed.”

Gastrointestinal cancers remain a leading cause of cancer-related deaths in China, and for patients with advanced colorectal and gastric cancers, treatment options are limited.

In an interview with CGTLive, Weijia Fang, MD, Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, and Tianhang Luo, MD, Gastrointestinal Surgery Department, Shanghai Changhai Hospital, discussed unmet needs for patients with advanced colorectal and gastric cancers and IMC001, an investigational chimeric antigen receptor (CAR) T-cell therapy which targets the EpCAM protein. Fang recently discussed the ongoing phase 1 clinical trial (NCT05028933) for IMC001 in a presentation at the European Society for Medical Oncology (ESMO) 2022 Congress, September 9-13, 2022, in Paris, France.

Fang explained the key findings that have come out of the clinical trial so far, discussing the safety profile and pointing out that no dose-limiting toxicities have been observed so far. Luo discussed potential advantages of IMC001 compared with current standards of care, noting that cytoreductive surgery has been an ineffective treatment for patients with advanced gastric cancers with metastasis.

For more coverage of ESMO 2022, click here.